PAE yields 19.90% · ABBV yields 3.12%● Live data
📍 ABBV pulled ahead of the other in Year 9
Combined, PAE + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PAE + ABBV for your $10,000?
PAE Incorporated provides operational solutions and outsourced services for the United States government, other allied governments, international organizations, and companies. The company operates through two segments, Global Mission Services and National Security Solutions. The Global Mission Services segment engages in logistics and stability operations, including lifecycle logistics operations, humanitarian, and stability operations; infrastructure management, such as mission operations support, space development and operations, and test and training ranges; and force readiness comprising the maintenance and repair of military and civilian vehicle fleets and aircraft. The National Security Solutions segment offers counter-threat solutions, such as training support and counter-terrorism solutions; information optimization services, including business process outsourcing services to government agencies, such as citizenship processing and litigation services, and systems support; and intelligence solutions comprising intelligence analysis, mission support, program management, engineering, and training solutions. PAE Incorporated was founded in 1955 and is headquartered in Falls Church, Virginia. As of February 15, 2022, PAE Incorporated operates as a subsidiary of Amentum Government Services Holdings LLC.
Full PAE Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.